Market Place
Sourcing Support
Pyxis Oncology to Host Investor Event on PYX-201 Data, Nov 20
11 Nov 2024 //
GLOBENEWSWIRE
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Pyxis Oncology Provides Corporate Update And Reports Q2 2024 Financials
14 Aug 2024 //
GLOBENEWSWIRE
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
29 Jul 2024 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Jun 2024 //
GLOBENEWSWIRE
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
10 Jun 2024 //
GLOBENEWSWIRE
Pyxis At Jefferies Healthcare Fireside Chat
30 May 2024 //
GLOBENEWSWIRE
Pyxis Oncology Provides Update, Q1 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
Pyxis to Present at the RBC Capital Markets Global Healthcare Conference
09 May 2024 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Mar 2024 //
GLOBENEWSWIRE
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
27 Mar 2024 //
GLOBENEWSWIRE
Pyxis Oncology Provides Corporate Update and Reports Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Pyxis Oncology Expands Board of Directors
13 Mar 2024 //
GLOBENEWSWIRE
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
07 Mar 2024 //
GLOBENEWSWIRE
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data
05 Mar 2024 //
GLOBENEWSWIRE
Pyxis Oncology Announces $50 Million Private Placement
27 Feb 2024 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Dec 2023 //
GLOBENEWSWIRE
Pyxis Oncology Announces Appointment of Ken Kobayashi as Chief Medical Officer
28 Nov 2023 //
GLOBENEWSWIRE
Hoping to pave a longer runway, Pyxis cuts staff, reprioritizes
08 Nov 2023 //
FIERCE BIOTECH
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program
07 Nov 2023 //
GLOBENEWSWIRE
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation
27 Sep 2023 //
GLOBENEWSWIRE
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Pyxis Oncology Successfully Completes Acquisition of Apexigen
23 Aug 2023 //
GLOBENEWSWIRE
Pyxis Oncology Reports Financial Results for Second-Quarter 2023
11 Aug 2023 //
GLOBENEWSWIRE
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
01 Aug 2023 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Jun 2023 //
GLOBENEWSWIRE
Apexigen Announces Phase 2 Data Evaluating Sotigalimab
03 Jun 2023 //
GLOBENEWSWIRE
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
30 May 2023 //
GLOBENEWSWIRE
Pyxis Oncology to Acquire Apexigen in $16M Deal
24 May 2023 //
CONTRACT PHARMA
Small SPAC to tiny sale: Apexigen sprints to Pyxis Oncology in $16M exit
24 May 2023 //
ENDPTS
Apexigen accepts Pyxis` $16M bid 300 days after going public
24 May 2023 //
FIERCE BIOTECH
Pyxis Oncology to Acquire Apexigen
24 May 2023 //
GLOBENEWSWIRE
Pyxis Oncology Reports Financial Results for the First Quarter 2023
11 May 2023 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Mar 2023 //
GLOBENEWSWIRE
Pyxis Reports Financial Results for the Fiscal Year Ended December 31, 2022
22 Mar 2023 //
GLOBENEWSWIRE
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201
16 Mar 2023 //
GLOBENEWSWIRE
Apexigen lays off 55% of staff and considers exit routes
28 Feb 2023 //
FIERCE BIOTECH
Apexigen Announces Review of Strategic Alternatives and Restructuring
27 Feb 2023 //
GLOBENEWSWIRE
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Conference
13 Feb 2023 //
GLOBENEWSWIRE
Apexigen Announces Approximately $2.8 Million Private Placement Financing
24 Jan 2023 //
GLOBENEWSWIRE
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab at ASCO
19 Jan 2023 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 Dec 2022 //
GLOBENEWSWIRE
Apexigen Reports Third Quarter 2022 Financial Results
15 Nov 2022 //
GLOBENEWSWIRE
Apexigen Announces +ve Interim Results of Ph2 Trial Sotigalimab with Doxorubicin
14 Nov 2022 //
GLOBENEWSWIRE
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody
11 Nov 2022 //
GLOBENEWSWIRE
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30
01 Nov 2022 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Sep 2022 //
GLOBENEWSWIRE
Apexigen Presents New Data from a Ph 2 Trial its CD40 Antibody, Sotigalimab
10 Sep 2022 //
GLOBENEWSWIRE
Apexigen to Participate in the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Apexigen Announces New Data from PII Trial Evaluating its CD40 Antibody
05 Sep 2022 //
PRESS RELEASE
Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
04 Sep 2022 //
PRESS RELEASE
Pyxis puts 2 drugs on backburner and a 3rd on the scrapheap
16 Aug 2022 //
FIERCEBIOTECH
Pyxis Oncology Reports Financial Results for the Second Quarter
15 Aug 2022 //
GLOBENEWSWIRE
Apexigen Completes Business Combination to Become a Publicly Listed IO Company
01 Aug 2022 //
GLOBENEWSWIRE
Apexigen and Brookline Capital Announce Effectiveness of Registration Statement
18 Jul 2022 //
GLOBENEWSWIRE
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jul 2022 //
GLOBENEWSWIRE
Apexigen to Participate in the Brookline Capital Markets Newport Symposium
11 Jul 2022 //
GLOBENEWSWIRE
Apexigen Announces Board Appointment and New Chair
29 Jun 2022 //
GLOBENEWSWIRE
Pyxis Oncology to Present at H.C. Wainwright PCDD Conference
28 Jun 2022 //
GLOBENEWSWIRE
Apexigen Appoints William Duke as Chief Financial Officer
08 Jun 2022 //
GLOBENEWSWIRE
